FORESIGHT
`
`News & Publications
`
`Contact
`
`We're Hiring!
`
`Technology
`
`Partnership
`
`About
`
`News & Publications
`
`Foresight Diagnostics Patent Issued for Minimal Residual Disease
`Detection Technology
`Aurora, Colorado, September 27, 2022
`
`Foresight Diagnostics, Inc, a leader in cancer diagnostics and cancerrelapse testing, announced today that
`the U.S. Patent and Trademark Office (USPTO) has granted the company patent No. 11,447,833for the
`detection of minimal residual disease (MRD)using its personalized phased variant detection platform. "We
`are pleased that the USPTO has recognized the novel nature of our proprietary technology and are excited
`about the impactwebelieve this technologywill have on thelives of cancer patients," said Dr. Jake Chabon,
`Ph.D., Chief Executive Officer of Foresight Diagnostics.
`
`This granted patent covers Foresight's PhasED-Seq technology and the workflow behind the Foresight Solid
`Tumor RecurrenceTest, an assay used to detect minimum residual disease (MRD) from the plasma of
`cancerpatients using DNA sequencing. Thetest is custom designed for each patient to track phased variants
`identified from tumor tissue samples using whole genome sequencing. Thetest offers unprecedented
`sensitivity for MRD detection, enabling a limit of detection below one part per million.
`
`"Ultra-sensitive MRD tests are essential to detect residual disease and recurrence following completion of
`curative intent therapies," said Dr. Ash Alizadeh, MD/Ph.D., co-founder and Chief Medical Advisor at
`Foresight. "PhasED-Seq has been used in more than 20 different clinical studies, and can predict cancer
`relapse when tumor burdenis low and patients are morelikely to favorably respondto anti-tumortherapy.
`Sensitivity for MRD detection is importantfor all types of cancer andis particularly critical for cancers that
`shedrelatively small amountsof circulating tumor DNA (ctDNA) into the bloodstream suchaslung and breast
`cancer"
`
`"Issuance of this patent by the USPTOis an important milestonein our quest to bring Foresight's best-in-
`class MRDtesting to cancerpatients," said Dr. Chabon. "The increased sensitivity of the PhasED-Seq MRD
`testing platform has the potential to dramatically improve patient outcomes, both in termsof identifying
`candidates for new therapeutic regimens as well as relieving patient anxiety around cancerrelapse. We've
`seen significant commercial interest in our MRDtesting platform from both academic and industry partners
`and are already planning discussions with the FDAto identify the most expedient regulatory pathwayto bring
`this test to patients. We're excited to see how oncologists and drug developers can use PhasED-Seq to
`enhancecancercare."
`
`About Foresight Diagnostics
`
`Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The
`company has developed a novelliquid biopsy testing platform for the measurementof minimalresidual
`disease (MRD)thatis significantly more sensitive (with a detection limit below 0.0001% or one part-per-
`million) than existing tests. The improved sensitivity of the Foresight MRD assays can provide actionable
`information to physicians and biopharmaceutical companies to enable more personalized treatment
`approachesfor patients with solid tumors and B-cell malignancies. For more information, pleasevisit
`foresight-dx.com and follow us on Twitter and LinkedIn.
`
`About PhasED-Seq
`
`The Foresight MRDplatform is based on the Phased variant Enrichment and Detection by Sequencing
`(PhasED-Seq) technology. PhasED-Seq lowersthe errorprofile of mutation detection in sequencing data by
`requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By
`detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA
`(i.e., ctDNA) from healthy cell free DNA - enabling detection of ctDNAat levels below onepart-per-million
`(<.0001%). PhasED-Seq has been exclusively validated in thousandsof patient samples.
`
`
`
`FORESIGHT
`DIAGNOSTICS
`
`Accreditati
`ereaatons:
`
`CUA: 0602226539 SO 27001 Cert No. C1342ISMS498-12.2
`
`TEAM
`
`AREER
`CAREERS
`
`INTACT
`CONTAC
`
`x
`y in
`
`Personalis EX2006.001
`Personalis EX2006.001
`
`